Becton, Dickinson and Company

Becton, Dickinson and Company

BDXยทNYSE

$145.61

+0.19%
HealthcareMedical - Instruments & Supplies

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

At a Glance

Live Snapshot
Market Cap$52.75B
EPS5.8400
P/E Ratio24.93
Earnings Date08/06/2026
3Y+16.0%
5Y+36.0%
10Y+75.0%
3Y-6.0%
5Y+92.0%
10Y+72.0%
3Y+30.0%
5Y-3.0%
10Y+34.0%
Becton, Dickinson and Company

Becton, Dickinson and Company Profit Bridge

BDX ยท NYSE
Revenue21.84B
Cost of Goods Sold (11.91B)
Gross Profit9.92B
Operating Expenses (7.35B)
Operating Income2.58B
Interest Expense (613.00M)
Other Income/Expense-696.00M
Pretax Income1.88B
Income Tax (204.00M)
Net Income1.68B
Net Income
1.68B

Profitability Analysis

Gross Margin

45.4%

Strong gross margins indicate healthy pricing and efficient production or service delivery.

Operating Margin

11.8%

Acceptable margins but limited operational leverage. Operating expense control is important.

Net Profit Margin

7.7%

Moderate profitability with room for improvement. Monitor interest expenses and tax efficiency.

Effective Tax Rate

10.8%

Below-average tax rate suggests effective tax planning, favorable jurisdictions, or tax credits.

Profitability Insight

Room for improvement: Moderate profitability with opportunities to enhance margins through better cost management or pricing strategy.

Becton, Dickinson and Company Income Statement

BDX โ€ข NYSE

Becton, Dickinson and Company Income StatementSep 2025Sep 2024Sep 2023Sep 2022Sep 2021Sep 2020Sep 2019Sep 2018Sep 2017Sep 2016Sep 2015Sep 2014Sep 2013Sep 2012Sep 2011Sep 2010Sep 2009Sep 2008Sep 2007Sep 2006
REVENUE
21.8B
20.2B
19.4B
18.9B
19.1B
16.1B
17.3B
16B
12.1B
12.5B
10.3B
8.4B
8.1B
7.7B
7.6B
7.1B
7B
7.1B
6.4B
5.7B
GROSS PROFIT
(11.9B)
(11.1B)
(11.2B)
(10.4B)
(10.5B)
(9.3B)
(9B)
(8.7B)
(6.1B)
(6.5B)
(5.6B)
(4.1B)
(3.9B)
(3.8B)
(3.6B)
(3.4B)
(3.3B)
(3.4B)
(3.1B)
(2.8B)
9.9B
9.1B
8.2B
8.5B
8.6B
6.8B
8.3B
7.3B
6B
6B
4.7B
4.3B
4.2B
4B
4B
3.7B
3.7B
3.6B
3.3B
2.9B
OPERATING INCOME
(7.3B)
(6.7B)
(6.1B)
(6.2B)
(6.4B)
(5.9B)
(6.5B)
(5.8B)
(4.4B)
(4.6B)
(3.6B)
(2.7B)
(2.9B)
(2.4B)
(2.3B)
(2.1B)
(2.1B)
(2.1B)
(2.1B)
(1.8B)
(5.3B)
(4.9B)
(4.7B)
(4.7B)
(4.7B)
(4.2B)
(4.3B)
(4B)
(2.9B)
(3B)
(2.6B)
(2.1B)
(2.4B)
(1.9B)
(1.8B)
(1.7B)
(1.7B)
(1.7B)
(1.6B)
(1.4B)
(1.3B)
(1.2B)
(1.2B)
(1.3B)
(1.3B)
(1B)
(1.1B)
(1B)
(770M)
(828M)
(632M)
(550M)
(494M)
(472M)
(470M)
(422.8M)
(404.6M)
(395.6M)
(360.1M)
(301.9M)
2.6B
2.4B
2.1B
2.3B
2.3B
912M
1.8B
1.5B
1.5B
1.4B
1.1B
1.6B
1.3B
1.6B
1.7B
1.6B
1.6B
1.5B
1.2B
1.1B
PRE-TAX INCOME
(613M)
(528M)
(452M)
(398M)
(469M)
(528M)
(639M)
(706M)
(521M)
(388M)
(371M)
(135M)
(138M)
(135M)
(84M)
(51.3M)
(40.4M)
(36.3M)
(0.0)
(0.0)
-575M
-365M
-403M
-382M
-460M
-521M
-627M
-641M
-445M
-367M
-356M
-89M
-98M
-85M
-41M
-16.1M
-7.2M
3M
0.0
0.0
(806M)
(681M)
(103M)
(230M)
(383M)
(662M)
(1.1B)
(740M)
(764M)
(728M)
(426M)
(0.0)
(1M)
(0.0)
-1M
(0.0)
(0.0)
(0.0)
(122.1M)
(53.3M)
-696M
-392M
-449M
-499M
-558M
-498M
-584M
-336M
-546M
-356M
-335M
-84M
-89M
-86M
-48M
-15.6M
-11.1M
1.5M
745K
-15.5M
1.9B
2B
1.7B
1.8B
1.7B
414M
1.2B
1.2B
976M
1.1B
739M
1.5B
1.2B
1.5B
1.6B
1.6B
1.6B
1.5B
1.2B
1.1B
NET INCOME
(204M)
(300M)
(132M)
(148M)
(88M)
(62M)
-57M
(862M)
-124M
(97M)
(44M)
(337M)
(236M)
(363M)
(417M)
(451.9M)
(411.2M)
(422.5M)
(347.8M)
(310.8M)
1.7B
1.7B
1.5B
1.8B
2.1B
874M
1.2B
311M
1.1B
976M
695M
1.2B
1.3B
1.2B
1.3B
1.3B
1.2B
1.1B
890M
752.3M

SEC Filings

BDX - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
8-K

8-K 2026

N/A

May 29, 2026
May 29, 2026
2026
8-K

8-K 2026

N/A

May 20, 2026
May 20, 2026
2026
8-K

8-K 2026

N/A

May 12, 2026
May 11, 2026
2026
8-K

8-K 2026

N/A

May 07, 2026
May 07, 2026
2026
8-K/A

8-K/A 2025 (Amended)

N/A

May 07, 2026
October 09, 2025
2025
10-Q

10-Q 2026 Q1

Q1

May 07, 2026
March 31, 2026
2026
8-K

8-K 2026

N/A

April 29, 2026
April 28, 2026
2026
8-K

8-K 2026

N/A

April 09, 2026
April 06, 2026
2026
8-K

8-K 2026

N/A

April 02, 2026
April 02, 2026
2026
8-K

8-K 2026

N/A

February 25, 2026
February 25, 2026
2026
Showing 1 to 10 of 600 filings